M
Masashi Mizokami
Researcher at Nagoya City University
Publications - 684
Citations - 37168
Masashi Mizokami is an academic researcher from Nagoya City University. The author has contributed to research in topics: Hepatitis B virus & Hepatitis C virus. The author has an hindex of 85, co-authored 650 publications receiving 34868 citations. Previous affiliations of Masashi Mizokami include National Institute of Advanced Industrial Science and Technology & University of Florida.
Papers
More filters
Journal ArticleDOI
Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study.
Naohiko Masaki,Yoko Yamagiwa,Takuro Shimbo,Kazumoto Murata,Masaaki Korenaga,Tatsuya Kanto,Masashi Mizokami +6 more
TL;DR: Regional disparities still exist in IFN therapy, and are strongly associated with treatment performance and outcome, and public health actions should be focused on how to construct and properly manage consultation networks between base hospitals and local clinics, especially in those regions with low population density.
Journal ArticleDOI
Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection.
Yasuhito Tanaka,Kousuke Hanada,Hideji Hanabusa,Fuat Kurbanov,Takashi Gojobori,Masashi Mizokami +5 more
TL;DR: HIV-positive patients would have a more diversified HCV population than HIV-negative patients due to less selective pressure from the immune system, according to the coalescence theory.
Journal ArticleDOI
Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma
Nobuharu Tamaki,Atsushi Kuno,Atsushi Matsuda,Hanako Tsujikawa,Ken Yamazaki,Yutaka Yasui,Kaoru Tsuchiya,Hiroyuki Nakanishi,Jun Itakura,Masaaki Korenaga,Masashi Mizokami,Masayuki Kurosaki,Michiie Sakamoto,Hisashi Narimatsu,Namiki Izumi +14 more
TL;DR: Results revealed that serum WFA-sialylated MUC1 was associated with histological feature of HCC and recurrence after curative therapy and it could be a novel marker of HPC/biliary features in H CC and of prognosis.
Journal ArticleDOI
Interferon-α therapy in patients dually infected with hepatitis C virus and GB virus C/hepatitis G virus — virological response of HGV and pretreatment HGV viremia level
Etsuro Orito,Masashi Mizokami,Kiyomi Yasuda,Kanji Sugihara,Makoto Nakamura,Motokazu Mukaide,Ken-ichi Ohba,Tatsunori Nakano,Takanobu Kato,Yutaka Kondo,Takashi Kumada,Ryuzo Ueda,Shiro Iino +12 more
TL;DR: There was no significant clinical and virological differences between the patients with dual infection and those with only HCV infection, and HGV shows sensitivity to IFN therapy, and in the patients who show a low pretreatment HGV RNA level, serum HGVRNA becomes undetectable by RT-PCR after cessation ofIFN therapy.
Journal ArticleDOI
Plasma Levels of Adiponectin and Primary Liver Cancer Risk in Middle-Aged Japanese Adults with Hepatitis Virus Infection: A Nested Case–Control Study
Takehiro Michikawa,Manami Inoue,Norie Sawada,Shizuka Sasazuki,Yasuhito Tanaka,Motoki Iwasaki,Taichi Shimazu,Taiki Yamaji,Masashi Mizokami,Shoichiro Tsugane +9 more
TL;DR: Higher plasma adiponectin levels were associated with an increased risk of primary liver cancer in middle-aged Japanese adults with hepatitis virus infection and may be a risk marker forPrimary liver cancer.